Eli Lilly expands multi‑year support for Team USA athlete recovery through Los Angeles 2028

Lilly expands multi‑year role supporting Team USA athlete recovery

Eli Lilly and Company is stepping up as the presenting partner of the U.S. Olympic and Paralympic Committee’s (USOPC) Team USA Athlete Recovery Program, committing multi‑year support that extends access after the Milano Cortina 2026 Winter Games through the Los Angeles 2028 cycle. The collaboration builds on Lilly’s existing role as an Official Partner in Health Equity and frames the company’s involvement as a long‑term investment in athlete health and well‑being beyond competition. Lilly’s support covers funding, advocacy and program expansion to reach a larger network of athletes over the next three years.

The program provides targeted rehabilitation and coordinated, holistic care for athletes with complex or extended recovery needs, prioritising long‑term outcomes whether athletes return to sport or transition to new careers. USOPC pilots in 2024 supported 10 Team USA athletes — six of whom qualified for Paris 2024 and together earned four medals including two golds — and USOPC Chief Medical Officer Dr. Jonathan Finnoff says the initiative offers “expertise, coordinated care, and support to help athletes navigate recovery journeys.” U.S. Paralympic triathlete Grace Norman credits the program with helping her reach the start line and become Paralympic champion in Paris after entering the cycle with an injury.

As presenting partner, Lilly also plans to collaborate on storytelling to spotlight recovery journeys and build awareness, athlete education, provider networks and measurement of outcomes. Jennifer Oleksiw, Lilly’s global chief customer officer, frames the expanded partnership as a commitment to holistic, long‑term support “rooted in the pursuit of health.” The USOPC will integrate the recovery program into athlete care pathways, track clinical and functional improvements, and report progress to stakeholders and fans globally and transparently, aiming to quantify impact as the program scales.

Lilly to present at TD Cowen health conference

Lilly announces participation in TD Cowen’s 46th Annual Health Care Conference on March 2, 2026, where CFO Lucas Montarce will appear in a fireside chat. A live audio webcast and a replay (available approximately 90 days) are provided on Lilly’s investor webcasts page.

Company emphasis on science and access

The company reiterates its identity as a medicine maker “turning science into healing,” citing nearly 150 years of discoveries and a scientific focus on biotechnology, chemistry and genetic medicine to address diabetes, obesity, Alzheimer’s, immune disorders and cancer, alongside commitments to diverse clinical trials and medicine accessibility. Media and investor contact details are provided in the release.